Phase II Study of cisplatin plus irinotecan for large cell neuroendocrine carcinoma
Phase 2
Recruiting
- Conditions
- arge cell neuroendocrine carcinoma
- Registration Number
- JPRN-UMIN000004796
- Lead Sponsor
- ational Cancer Research Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
1) unresectable disease with indication for chest radiotherapy 2) uncontrolled pleural/pericardial effusion 3) active concomitant malignancy 4) interstitial pneumonia or pulmonary fibrosis as determined by chest x-ray 5) watery diarrhea 6) intestinal obstruction or paralysis 7) symptomatic brain metastasis 8) severe complications: .uncontrolled angina, myocardial infarction within the previous 3 months, severe cardiac failure 9) pregnant or lactating women 10) psychological disease deemed unacceptable for inclusion to the study 11) severe drug allergy 12) doctor's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method